
## Katia A Mesquita

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2314191/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	In Vitro Surfactant Structure-Toxicity Relationships: Implications for Surfactant Use in Sexually Transmitted Infection Prophylaxis and Contraception. PLoS ONE, 2011, 6, e19850.	1.1	109
2	Mitochondrial metabolism directs stemness and differentiation in P19 embryonal carcinoma stem cells. Cell Death and Differentiation, 2014, 21, 1560-1574.	5.0	91
3	Mitochondria in Cancer Stem Cells: A Target for Therapy. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2013, 7, 102-114.	0.7	49
4	Mitochondrial biology in cancer stem cells. Seminars in Cancer Biology, 2017, 47, 18-28.	4.3	42
5	Melatonin antiproliferative effects require active mitochondrial function in embryonal carcinoma cells. Oncotarget, 2015, 6, 17081-17096.	0.8	28
6	Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma <i>In Situ</i> Induces Synthetic Lethality and Chemoprevention. Cancer Research, 2018, 78, 6818-6827.	0.4	26
7	ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers. Gynecologic Oncology, 2019, 153, 416-424.	0.6	26
8	PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers. Cancer Letters, 2020, 469, 124-133.	3.2	22
9	Cell quality control mechanisms maintain stemness and differentiation potential of P19 embryonic carcinoma cells. Autophagy, 2020, 16, 313-333.	4.3	18
10	Injectable laminin-biofunctionalized gellan gum hydrogels loaded with myoblasts for skeletal muscle regeneration. Acta Biomaterialia, 2022, 143, 282-294.	4.1	13
11	FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers. Cancers, 2021, 13, 1866.	1.7	12
12	Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers. Theranostics, 2021, 11, 8350-8361.	4.6	10
13	ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers. Cancers, 2019, 11, 1149.	1.7	9
14	Development and implementation of precision therapies targeting base-excision DNA repair in BRCA1-associated tumors. Expert Review of Precision Medicine and Drug Development, 2019, 4, 11-25.	0.4	1